.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Boehringer Ingelheim
Merck
Julphar
Accenture
Daiichi Sankyo
Cerilliant
Fuji
Citi

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,642,079

« Back to Dashboard

Which drugs does patent 8,642,079 protect, and when does it expire?


Patent 8,642,079 protects OSPHENA and is included in one NDA.

This patent has eighteen patent family members in seventeen countries.

Summary for Patent: 8,642,079

Title:Solid formulations of ospemifene
Abstract: This invention relates to a solid drug formulation comprising granulates containing a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with one or more intra-granular excipients.
Inventor(s): Lehtola; Veli-Matti (Turku, FI), Halonen; Kaija (Rusko, FI)
Assignee: Hormos Medical Corporation (Turku, FI)
Application Number:10/783,024
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes8,642,079► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,642,079

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2423113► Subscribe
Russian Federation2006133902► Subscribe
Portugal1718288► Subscribe
Norway20064262► Subscribe
MexicoPA06009546► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Deloitte
Chubb
Citi
Chinese Patent Office
US Army
Cipla
QuintilesIMS
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot